FDA Proposes Accelerated Approval Pathway for Ultra-Rare Disease Gene Therapies
The FDA released draft guidance establishing a new approval framework for individualized gene-editing and RNA-based therapies targeting ultra-rare diseases, allowing approvals based on small studies when traditional trials are not feasible.